HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ophthalmology M&A Engine Keeps Roaring As Akorn Buys Out Hi-Tech

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Raj Rai calls the transaction a “transformative event” for Akorn that will be instantly accretive and produce between $15 million and $20 million of run-rate synergies within 12 months. Acquisition of Hi-Tech adds prescription and OTC products, 18 filed ANDAs and increased manufacturing capability.

You may also be interested in...



With 100% Alcon Ownership, Novartis Forms New Eye Care Unit

Novartis reaches agreement to buy the part of Alcon it doesn't already own for $12.9 billion, ending months of squabbling with Alcon minority shareholders.

Valeant Pharmaceuticals To Buy Aton For $318 Mil.; Bolsters U.S. Specialty Business

Acquisition is expected to buffer sales that will be lost when Valeant's epilepsy drug Diastat faces generic competition later this year.

T-knife Taps Into Investor Interest in T-Cell Receptor Therapies

The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.

Topics

Related Companies

UsernamePublicRestriction

Register

RS124191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel